310 related articles for article (PubMed ID: 32198373)
21. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
[TBL] [Abstract][Full Text] [Related]
22. The Prostate Health Index and multi-parametric MRI improve diagnostic accuracy of detecting prostate cancer in Asian populations.
Ye C; Ho JN; Kim DH; Song SH; Kim H; Lee H; Jeong SJ; Hong SK; Byun SS; Ahn H; Hwang SI; Lee HJ; Lee S
Investig Clin Urol; 2022 Nov; 63(6):631-638. PubMed ID: 36347552
[TBL] [Abstract][Full Text] [Related]
23. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
24. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
25. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
[TBL] [Abstract][Full Text] [Related]
26. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
[TBL] [Abstract][Full Text] [Related]
28. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
29. Combining Prostate-Specific Antigen Parameters With Prostate Imaging Reporting and Data System Score Version 2.0 to Improve Its Diagnostic Accuracy.
Baruah SK; Das N; Baruah SJ; Rajeev TP; Bagchi PK; Sharma D; Phukan M
World J Oncol; 2019 Dec; 10(6):218-225. PubMed ID: 31921377
[TBL] [Abstract][Full Text] [Related]
30. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
[TBL] [Abstract][Full Text] [Related]
31. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
32. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
33. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
35. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
36. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
[TBL] [Abstract][Full Text] [Related]
37. MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Huang C; Song G; Wang H; Ji G; Li J; Chen Y; Fan Y; Fang D; Xiong G; Xin Z; Zhou L
Biomed Res Int; 2018; 2018():6368309. PubMed ID: 30276213
[TBL] [Abstract][Full Text] [Related]
38. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.
Zhang Q; Wang W; Zhang B; Shi J; Fu Y; Li D; Guo S; Zhang S; Huang H; Jiang X; Zhou W; Guo H
Int Urol Nephrol; 2017 Mar; 49(3):439-448. PubMed ID: 28005230
[TBL] [Abstract][Full Text] [Related]
39. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy.
Stejskal J; Adamcová V; Záleský M; Novák V; Čapoun O; Fiala V; Dolejšová O; Sedláčková H; Veselý Š; Zachoval R
World J Urol; 2021 Jun; 39(6):1889-1895. PubMed ID: 32761380
[TBL] [Abstract][Full Text] [Related]
40. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
Dwivedi DK; Kumar R; Dwivedi AK; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
J Magn Reson Imaging; 2018 May; 47(5):1227-1236. PubMed ID: 28872226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
